​

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACAD Stock Forecast

ACADIA Pharmaceuticals stock forecast is as follows: an average price target of $25.50 (represents a 52.42% upside from ACAD’s last price of $16.73) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.

ACAD Price Target

The average price target for ACADIA Pharmaceuticals (ACAD) is $25.50 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $31.00 to $20.00. This represents a potential 52.42% upside from ACAD's last price of $16.73.

ACAD Analyst Ratings

Buy

According to 18 Wall Street analysts, ACADIA Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ACAD stock is 0 'Strong Buy' (0.00%), 12 'Buy' (66.67%), 5 'Hold' (27.78%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).

ACADIA Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 07, 2024Jeffrey HungMorgan Stanley$20.00$18.856.10%19.55%
Jun 26, 2024Keith TapperBMO Capital$31.00$15.50100.00%85.30%
May 09, 2024Andrew FeinH.C. Wainwright$27.00$17.1357.62%61.39%
May 09, 2024Joel BeattyRobert W. Baird$28.00$17.1363.46%67.36%
May 09, 2024Uy EarMizuho Securities$21.00$17.1322.59%25.52%
Apr 30, 2024Ashwani VermaUBS$27.00$17.1057.89%61.39%
Mar 12, 2024Ashwani VermaUBS$33.00$19.9865.17%97.25%
Mar 12, 2024Jay OlsonOppenheimer$19.00$19.98-4.90%13.57%
Mar 12, 2024Ami FadiaNeedham$32.00$19.9860.16%91.27%
Mar 12, 2024Sumant KulkamiCanaccord Genuity$33.00$19.9865.17%97.25%
Mar 12, 2024Jason ButlerJMP Securities$39.00$19.9895.20%133.11%
Jan 24, 2024Ami FadiaNeedham$37.00$27.1936.08%121.16%
Nov 14, 2022J.P. Morgan$17.00$15.926.78%1.61%
Aug 09, 2022Morgan Stanley$18.00$16.519.02%7.59%
Aug 09, 2022Mizuho Securities$19.00$16.3116.49%13.57%
Aug 09, 2022Goldman Sachs$15.00$16.62-9.75%-10.34%
Aug 09, 2022RBC Capital$21.00$16.6226.35%25.52%
Aug 09, 2022H.C. Wainwright$25.00$16.6250.42%49.43%
Aug 09, 2022Leerink Partners$21.00$16.6226.35%25.52%
Aug 08, 2022Cowen & Co.$21.00$16.8324.78%25.52%
Jul 15, 2022Morgan Stanley$22.00$15.2344.45%31.50%
Jul 11, 2022Leerink Partners$27.00$15.7471.54%61.39%
Jun 22, 2022Citigroup$19.00$13.0146.04%13.57%
Jun 21, 2022Oppenheimer$19.00$12.5551.35%13.57%
Jun 21, 2022Cantor Fitzgerald$26.00$12.71104.56%55.41%
Jun 21, 2022RBC Capital$26.00$19.5133.26%55.41%
Jun 21, 2022H.C. Wainwright$20.00$19.512.51%19.55%
Apr 19, 2022Mizuho Securities$27.00$21.8023.88%61.39%
Mar 20, 2022Sumant KulkamiCanaccord Genuity$31.00$25.3822.14%85.30%
Mar 01, 2022Paul MatteisStifel Nicolaus$20.00$25.07-20.22%19.55%
Mar 01, 2022Neena Bitritto-GargCitigroup$32.00$25.0727.64%91.27%
Mar 01, 2022Tazeen AhmadBank of America Securities$31.00$25.0723.65%85.30%
Mar 01, 2022Andrew FeinH.C. Wainwright$36.00$25.0743.60%115.18%
Feb 28, 2022Marc GoodmanLeerink Partners$31.00$25.4122.00%85.30%
Dec 21, 2021Yatin SunejaGuggenheim$28.00$21.4530.54%67.36%
Dec 21, 2021Ritu BaralCowen & Co.$32.00$21.4549.18%91.27%
Dec 07, 2021Jay OlsonOppenheimer$23.00$21.327.88%37.48%
Aug 04, 2021Cory KasimovJ.P. Morgan$34.00$21.0561.52%103.23%
Apr 19, 2021Pito ChickeringDeutsche Bank$62.00$20.72199.23%270.59%

The latest ACADIA Pharmaceuticals stock forecast, released on Aug 07, 2024 by Jeffrey Hung from Morgan Stanley, set a price target of $20.00, which represents a 6.10% increase from the stock price at the time of the forecast ($18.85), and a 19.55% increase from ACAD last price ($16.73).

ACADIA Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts--12
Avg Price Target--$28.92
Last Closing Price$16.73$16.73$16.73
Upside/Downside-100.00%-100.00%72.86%

In the current month, the average price target of ACADIA Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ACADIA Pharmaceuticals's last price of $16.73. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 17, 2024GuggenheimBuyBuyHold
Oct 10, 2024UBSBuyBuyHold
Aug 07, 2024RBC CapitalEqual-WeightEqual-WeightHold
Aug 07, 2024Morgan StanleyOverweightEqual-WeightDowngrade
Jun 26, 2024BMO CapitalBuyOutperformInitialise
Jun 25, 2024RBC CapitalBuyBuyHold
May 09, 2024H.C. WainwrightBuyBuyHold
Apr 30, 2024RBC CapitalBuyBuyHold
Apr 30, 2024UBSBuyBuyHold
Mar 25, 2024RBC CapitalBuyBuyHold
Mar 12, 2024OppenheimerPerformPerformHold
Feb 28, 2024OppenheimerMarket OutperformMarket OutperformHold
Jan 24, 2024RBC CapitalMarket OutperformMarket OutperformHold
Jan 24, 2024NeedhamHoldBuyUpgrade
Dec 29, 2023BenchmarkBuyBuyHold
Dec 29, 2023UBSMarket OutperformMarket OutperformHold
Dec 19, 2023Morgan StanleyEqual-WeightOverweightUpgrade
Nov 06, 2023Mizuho SecuritiesBuyUpgrade
Jul 14, 2023JMP SecuritiesMarket PerformMarket PerformHold
Jul 14, 2023NeedhamHoldHoldHold
Mar 14, 2023CitigroupNeutralNeutralHold
Mar 14, 2023Canaccord GenuityBuyBuyHold
Feb 28, 2023Cantor FitzgeraldOverweightOverweightHold
Feb 28, 2023NeedhamHoldHoldHold
Feb 28, 2023Raymond JamesMarket PerformMarket PerformHold
Jan 03, 2023GuggenheimBuyUpgrade
Nov 03, 2022Goldman SachsNeutralSellDowngrade
Aug 09, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Aug 09, 2022SVB LeerinkBuyBuyHold
Aug 09, 2022Goldman SachsNeutralNeutralHold
Aug 09, 2022RBC CapitalOutperformOutperformHold
Aug 09, 2022BMO CapitalBuyBuyHold
Aug 09, 2022SVB LeerinkOutperformOutperformHold
Aug 08, 2022Cowen & Co.OutperformOutperformHold
Jul 15, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jul 11, 2022SVB LeerinkOutperformOutperformHold
Jun 22, 2022CitigroupBuyBuyHold
Jun 21, 2022OppenheimerPerformPerformHold
Jun 21, 2022JefferiesBuyDowngrade
Jun 21, 2022Cantor FitzgeraldOverweightOverweightHold
Jun 21, 2022RBC CapitalOutperformOutperformHold
Jun 20, 2022H.C. WainwrightBuyBuyHold
Mar 20, 2022Canaccord GenuityBuyUpgrade
Apr 06, 2021Morgan StanleyOverweightOverweightHold

ACADIA Pharmaceuticals's last stock rating was published by Guggenheim on Oct 17, 2024. The company gave ACAD a "Buy" rating, the same as its previous rate.

ACADIA Pharmaceuticals Financial Forecast

ACADIA Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$211.70M$165.24M$118.46M$136.49M$130.71M$134.56M$115.47M$130.76M$131.61M$115.22M$106.55M$121.01M$120.58M$110.10M$90.07M$98.33M$94.59M$83.20M$62.96M$48.87M$15.29M
Avg Forecast$272.22M$265.33M$256.63M$234.84M$276.08M$248.83M$235.95M$208.31M$223.79M$192.32M$166.18M$120.06M$134.23M$138.76M$130.41M$121.91M$135.39M$127.93M$124.90M$112.01M$122.76M$118.82M$103.41M$90.75M$96.69M$88.49M$72.54M$60.93M$61.09M$15.50M
High Forecast$307.87M$300.08M$290.25M$242.15M$367.48M$248.95M$235.95M$208.31M$228.53M$192.38M$187.94M$135.79M$151.82M$138.76M$130.41M$121.91M$135.39M$127.93M$124.90M$112.01M$122.76M$118.82M$103.41M$90.75M$96.69M$88.49M$72.54M$60.93M$73.30M$18.60M
Low Forecast$253.97M$247.54M$239.43M$227.40M$257.35M$248.71M$235.95M$208.31M$214.31M$192.26M$155.04M$112.01M$125.23M$138.76M$130.41M$121.91M$135.39M$127.93M$124.90M$112.01M$122.76M$118.82M$103.41M$90.75M$96.69M$88.49M$72.54M$60.93M$48.87M$12.40M
# Analysts11141377111471376686711713999955551214
Surprise %---------1.10%0.99%0.99%1.02%0.94%1.03%0.95%0.97%1.03%0.92%0.95%0.99%1.01%1.06%0.99%1.02%1.07%1.15%1.03%0.80%0.99%

ACADIA Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 14 analysts is $223.79M, with a low forecast of $214.31M, and a high forecast of $228.53M. ACAD's average Quarter revenue forecast represents a 5.71% increase compared to the company's last Quarter revenue of $211.70M (Sep 23).

ACADIA Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11141377111471376686711713999955551214
EBITDA---------$-57.78M$3.04M$-53.58M$-46.06M$-30.87M$-33.65M$-112.50M$-42.24M$-13.68M$-42.34M$-65.33M$-64.95M$-82.91M$-39.20M$-84.37M$-48.73M$-41.59M$-53.88M$-84.14M$-52.89M$-87.20M
Avg Forecast$-121.66M$-118.58M$-114.69M$-104.95M$-123.39M$-111.21M$-105.45M$-176.77M$-100.02M$-85.95M$-74.27M$-160.70M$-40.66M$-62.54M$-58.78M$-146.09M$-61.02M$-57.66M$-56.30M$-78.89M$-55.33M$-53.56M$-46.61M$-68.55M$-43.58M$-39.88M$-32.69M$-72.82M$-63.47M$-88.40M
High Forecast$-113.50M$-110.63M$-107.00M$-101.63M$-115.01M$-111.15M$-105.45M$-141.42M$-95.78M$-85.92M$-69.29M$-128.56M$-32.53M$-62.54M$-58.78M$-116.88M$-61.02M$-57.66M$-56.30M$-63.11M$-55.33M$-53.56M$-46.61M$-54.84M$-43.58M$-39.88M$-32.69M$-58.25M$-50.77M$-70.72M
Low Forecast$-137.59M$-134.11M$-129.72M$-108.22M$-164.23M$-111.26M$-105.45M$-212.13M$-102.13M$-85.98M$-83.99M$-192.85M$-48.79M$-62.54M$-58.78M$-175.31M$-61.02M$-57.66M$-56.30M$-94.67M$-55.33M$-53.56M$-46.61M$-82.26M$-43.58M$-39.88M$-32.69M$-87.38M$-76.16M$-106.08M
Surprise %---------0.67%-0.04%0.33%1.13%0.49%0.57%0.77%0.69%0.24%0.75%0.83%1.17%1.55%0.84%1.23%1.12%1.04%1.65%1.16%0.83%0.99%

7 analysts predict ACAD's average Quarter EBITDA for Sep 23 to be $-85.95M, with a high of $-85.92M and a low of $-85.98M. This is -2930.06% lower than ACADIA Pharmaceuticals's previous annual EBITDA (Jun 23) of $3.04M.

ACADIA Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11141377111471376686711713999955551214
Net Income---------$-65.18M$1.11M$-43.02M$-41.73M$-27.18M$-34.01M$-113.06M$-43.09M$-14.46M$-43.87M$-66.45M$-66.76M$-84.66M$-42.14M$-88.02M$-53.04M$-41.98M$-54.94M$-85.30M$-54.30M$-87.84M
Avg Forecast$37.03M$25.34M$24.10M$7.06M$38.36M$22.95M$29.52M$-178.52M$48.01M$-74.40M$-16.25M$-162.29M$-41.48M$-32.27M$-41.17M$-147.54M$-39.48M$-43.12M$-50.59M$-80.24M$-78.70M$-63.74M$-72.98M$-71.52M$-60.30M$-66.77M$-75.53M$-73.82M$-65.16M$-89.05M
High Forecast$43.34M$29.66M$28.20M$7.57M$118.56M$23.78M$29.58M$-142.82M$88.52M$-67.91M$-14.84M$-129.83M$-33.18M$-32.27M$-41.17M$-118.03M$-39.48M$-43.12M$-50.59M$-64.19M$-78.70M$-63.74M$-72.98M$-57.21M$-60.30M$-66.77M$-75.53M$-59.06M$-52.12M$-71.24M
Low Forecast$33.81M$23.13M$22.00M$6.56M$-12.20M$22.11M$29.47M$-214.23M$34.51M$-87.07M$-19.02M$-194.75M$-49.77M$-32.27M$-41.17M$-177.05M$-39.48M$-43.12M$-50.59M$-96.29M$-78.70M$-63.74M$-72.98M$-85.82M$-60.30M$-66.77M$-75.53M$-88.58M$-78.19M$-106.86M
Surprise %---------0.88%-0.07%0.27%1.01%0.84%0.83%0.77%1.09%0.34%0.87%0.83%0.85%1.33%0.58%1.23%0.88%0.63%0.73%1.16%0.83%0.99%

ACADIA Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-74.40M, with a range of $-87.07M to $-67.91M. ACAD's average Quarter net income forecast represents a -6778.45% decrease compared to the company's last Quarter net income of $1.11M (Jun 23).

ACADIA Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11141377111471376686711713999955551214
SG&A---------$97.89M$95.97M$101.23M$104.40M$78.11M$89.90M$96.68M$105.91M$81.67M$96.79M$111.66M$120.75M$81.59M$84.34M$101.97M$91.87M$72.70M$67.98M$93.09M$60.93M$65.75M
Avg Forecast$213.74M$208.32M$201.50M$184.38M$216.77M$195.37M$185.25M$152.66M$175.71M$151.00M$130.48M$94.27M$101.94M$108.95M$102.39M$95.72M$106.30M$100.45M$98.07M$87.94M$96.39M$93.30M$81.19M$82.85M$75.92M$69.48M$56.96M$47.84M$47.96M$12.17M
High Forecast$241.73M$235.61M$227.89M$190.13M$288.53M$195.46M$185.25M$183.19M$179.43M$151.05M$147.57M$106.61M$122.33M$108.95M$102.39M$95.72M$106.30M$100.45M$98.07M$87.94M$96.39M$93.30M$81.19M$99.42M$75.92M$69.48M$56.96M$47.84M$57.55M$14.60M
Low Forecast$199.41M$194.36M$187.99M$178.54M$202.06M$195.28M$185.25M$122.13M$168.27M$150.95M$121.73M$87.95M$81.55M$108.95M$102.39M$95.72M$106.30M$100.45M$98.07M$87.94M$96.39M$93.30M$81.19M$66.28M$75.92M$69.48M$56.96M$47.84M$38.37M$9.73M
Surprise %---------0.65%0.74%1.07%1.02%0.72%0.88%1.01%1.00%0.81%0.99%1.27%1.25%0.87%1.04%1.23%1.21%1.05%1.19%1.95%1.27%5.40%

ACADIA Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $175.71M, based on 14 Wall Street analysts, with a range of $168.27M to $179.43M. The forecast indicates a 79.50% rise compared to ACAD last annual SG&A of $97.89M (Sep 23).

ACADIA Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11141377111471376686711713999955551214
EPS---------$-0.40$0.01$-0.27$-0.26$-0.17$-0.21$-0.70$-0.27$-0.09$-0.27$-0.42$-0.42$-0.54$-0.27$-0.57$-0.34$-0.29$-0.38$-0.59$-0.44$-0.72
Avg Forecast$0.22$0.15$0.14$0.04$0.23$0.14$0.18$0.05$0.29$-0.45$-0.10$-0.21$-0.25$-0.19$-0.25$-0.62$-0.24$-0.26$-0.30$-0.53$-0.47$-0.38$-0.44$-0.48$-0.36$-0.40$-0.45$-0.52$-0.66$-0.74
High Forecast$0.26$0.18$0.17$0.05$0.71$0.14$0.18$0.05$0.53$-0.41$-0.09$-0.20$-0.23$-0.19$-0.25$-0.62$-0.24$-0.26$-0.30$-0.53$-0.47$-0.38$-0.44$-0.48$-0.36$-0.40$-0.45$-0.52$-0.53$-0.59
Low Forecast$0.20$0.14$0.13$0.04$-0.07$0.13$0.18$0.05$0.21$-0.52$-0.11$-0.25$-0.29$-0.19$-0.25$-0.62$-0.24$-0.26$-0.30$-0.53$-0.47$-0.38$-0.44$-0.48$-0.36$-0.40$-0.45$-0.52$-0.79$-0.89
Surprise %---------0.89%-0.07%1.26%1.05%0.88%0.85%1.13%1.14%0.35%0.89%0.79%0.89%1.41%0.61%1.19%0.94%0.72%0.84%1.13%0.67%0.97%

According to 7 Wall Street analysts, ACADIA Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.45, with a low estimate of $-0.52 and a high estimate of $-0.41. This represents a -6683.82% decrease compared to ACAD previous annual EPS of $0.01 (Jun 23).

ACADIA Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
ATHAAthira Pharma$0.59$18.002950.85%Buy
RVPHReviva Pharmaceuticals$1.40$10.00614.29%Buy
CABACabaletta Bio$2.75$16.33493.82%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
VKTXViking Therapeutics$46.70$97.80109.42%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
ACADACADIA Pharmaceuticals$17.41$25.5046.47%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
PTCTPTC Therapeutics$47.02$48.002.08%Hold

ACAD Forecast FAQ

Is ACADIA Pharmaceuticals a good buy?

Yes, according to 18 Wall Street analysts, ACADIA Pharmaceuticals (ACAD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 66.67% of ACAD's total ratings.

What is ACAD's price target?

ACADIA Pharmaceuticals (ACAD) average price target is $25.5 with a range of $20 to $31, implying a 52.42% from its last price of $16.73. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ACADIA Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ACAD stock, the company can go up by 52.42% (from the last price of $16.73 to the average price target of $25.5), up by 85.30% based on the highest stock price target, and up by 19.55% based on the lowest stock price target.

Can ACADIA Pharmaceuticals stock reach $30?

ACAD's highest twelve months analyst stock price target of $31 supports the claim that ACADIA Pharmaceuticals can reach $30 in the near future.

What are ACADIA Pharmaceuticals's analysts' financial forecasts?

ACADIA Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $969.17M (high $1.06B, low $950.33M), average EBITDA is $-517M (high $-473M, low $-593M), average net income is $-87.693M (high $29.1M, low $-175M), average SG&A $750.05M (high $852.44M, low $704.72M), and average EPS is $0.595 (high $1.08, low $0.286). ACAD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.03B (high $1.14B, low $968.34M), average EBITDA is $-460M (high $-433M, low $-510M), average net income is $93.53M (high $108.76M, low $85.49M), average SG&A $807.94M (high $895.36M, low $760.3M), and average EPS is $0.563 (high $0.655, low $0.514).

Did the ACAD's actual financial results beat the analysts' financial forecasts?

Based on ACADIA Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $517.24M, which missed the average analysts forecast of $525.32M by -1.54%. Apple's EBITDA was $-224M, missing the average prediction of $-308M by -27.42%. The company's net income was $-216M, missing the average estimation of $-262M by -17.71%. Apple's SG&A was $369.09M, missing the average forecast of $409M by -9.76%. Lastly, the company's EPS was $-1.34, beating the average prediction of $-1.307 by 2.52%. In terms of the last quarterly report (Sep 2023), ACADIA Pharmaceuticals's revenue was $211.7M, beating the average analysts' forecast of $192.32M by 10.08%. The company's EBITDA was $-57.776M, missing the average prediction of $-85.949M by -32.78%. ACADIA Pharmaceuticals's net income was $-65.176M, missing the average estimation of $-74.398M by -12.40%. The company's SG&A was $97.89M, missing the average forecast of $151M by -35.17%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.448 by -10.65%